Regentis signs exclusive deal with AMI to distribute GelrinC in Israel

RGNT•2026-11-09

Regentis Biomaterials entered a four-year exclusive distribution agreement with AMI Medical Technologies to commercialize its GelrinC knee cartilage repair implant in Israel. The agreement includes minimum purchase requirements, with initial revenue contributions expected in 2027.

1. Distribution agreement

Regentis Biomaterials entered a four-year exclusive distribution agreement with AMI Medical Technologies to commercialize GelrinC in Israel. The implant has regulatory approval from Israel's Ministry of Health. The partners will seek reimbursement coverage from Israeli health maintenance organizations, and the agreement includes minimum purchase requirements with initial revenue contributions expected in 2027.

Regentis signs exclusive deal with AMI to distribute GelrinC in Israel

1. Distribution agreement

Related News

BitMine says ETH holdings reach 6.07 million tokens, total crypto and cash holdings hit $14.3 billion

Peru files for offering of two-part global bonds; size not disclosed

Nasdaq pauses trading in ONCO for volatility at 9:50 a.m.

NRG Energy in talks with financing partners for data center buildout, announcement targeted by year-end

US FDA requires safety labeling changes for GLP-1 drugs over eye condition risk